Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn

Transplant Immunology

Volumn 10, Issue 2-3, 2002, Pages 191-198

  Hadley, Andrew G ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Anti D; Blood group serology; Chemiluminescence; Cytotoxicity; Haemolytic disease of the newborn

Indexed keywords

ALLOANTIBODY; BLOOD GROUP ANTIGEN; FC RECEPTOR; HLA ANTIBODY; IMMUNOGLOBULIN G; MATERNAL ANTIBODY;

ACCURACY; ALLOIMMUNIZATION; ANALYZER; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN STRUCTURE; ASSAY; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP RH; CELL ASSAY; CHEMOLUMINESCENCE; CLASSIFICATION; CORRELATION ANALYSIS; DENSITY; DISEASE SEVERITY; EFFECTOR CELL; FETUS; FETUS CELL; GENETIC POLYMORPHISM; GLYCOSYLATION; HAPLOTYPE; HLA SYSTEM; HUMAN; KILLER CELL; LABORATORY TEST; MATERNAL BLOOD; MATURATION; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEWBORN; NEWBORN HEMOLYTIC DISEASE; PLACENTAL TRANSFER; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVIEW; SEROLOGY; SPLEEN FUNCTION; TISSUE DISTRIBUTION;

ABO BLOOD-GROUP SYSTEM; ADULT; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BLOOD GROUP INCOMPATIBILITY; CHEMILUMINESCENT MEASUREMENTS; ERYTHROBLASTOSIS, FETAL; ERYTHROCYTES; FEMALE; FETAL BLOOD; FETAL DISEASES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC TESTS; INFANT, NEWBORN; ISOANTIBODIES; MATERNAL-FETAL EXCHANGE; MONOCYTES; PHAGOCYTOSIS; PREGNANCY; RECEPTORS, IGG; RH ISOIMMUNIZATION; RH-HR BLOOD-GROUP SYSTEM; SEVERITY OF ILLNESS INDEX;

EID: 0036348272     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(02)00065-5     Document Type: Review

References (68)

1. Production of atypical alloantibodies in Rh(D)-sensitized pregnancies managed by intrauterine investigation methods
2. Maternal serum anti-D antibody concentration and assessment of rhesus isoimmunization
3. Detection of fetal erythrocytes in maternal blood postpartum with the fluorescence-activated cell sorter
4. The prevention of Rh immunisation
5. Rh immunization and its prevention
6. Amniocentesis and isoimmunization
7. Plasmapheresis in Rh hemolytic disease, the danger of amniocentesis
8. Induction of additional red cell alloantibodies after intrauterine transfusions
9. Serological factors as possible causes in spontaneous abortions
10. The effect of Rh genotypes on severity in haemolytic disease of the newborn
11. HLA phenotypes and severe Rh(D) immunization
12. Human IgG subclasses in maternal and fetal serum
13. A major histocompatibility complex class I-like Fc receptor cloned from human placenta: Possible role in transfer of immunoglobulin G from mother to fetus
14. Elevation of cord over maternal IgG immunoglobulin, evidence for an active placental IgG transport
15. Anti-D concentration in mother and child in haemolytic disease of the newborn
16. Transplacental IgG subclass concentrations in pregnancies at risk of haemolytic disease of the newborn
17. Selective placental transport of maternal IgG to the fetus
18. Molecular basis of Fc receptor function
19. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies
20. Functional interactions of red cells sensitised by IgG1 and IgG3 human monoclonal anti-D with enzyme-modified human monocytes and FcR-bearing cell lines
21. Blockade of clearance of immune complexes by an anti-FcR monoclonal antibody
22. IgG receptor roles in red cell binding to monocytes and macrophages
23. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid lines is dependent on culture method and affects Fcγ receptor-mediated functional activity
24. ADCC (K-cell) lysis of human erythrocytes sensitized with Rhesus alloantibodies. III. Comparison of IgG anti-D agglutinating and lytic (ADCC) activity and the role of IgG subclasses
25. Anti-Rh(D) IgG subclasses and severity of Rh hemolytic disease of the newborn
26. Immunoglobulin G subclasses and isoimmunized pregnancy outcome
27. Correlation of serological, quantitative and cell-mediated functional assays of maternal alloantibodies with the severity of haemolytic disease of the newborn
28. Mononuclear phagocyte assays, AutoAnalyzer quantitation and IgG subclasses of maternal anti-RhD in the prediction of the severity of haemolytic disease in the fetus before 32 weeks gestation
29. IgG subclasses and Gm allotypes of anti-D antibodies during pregnancy: Correlation with the gravity of fetal disease
30. Correlation of IgG subclass with the severity of hemolytic disease of the newborn
31. Serological and immunological characteristics of maternal anti-Rh(D) antibodies in predicting the severity of haemolytic disease of the newborn
32. Anti-D concentrations in fetal and maternal serum and amniotic fluid in rhesus allo-immunised pregnancies
33. Erythropoietic suppression in fetal anaemia because of Kell alloimmunization
34. Fetal anaemia due to anti-K may result from immune destruction of early erythroid progenitors
35. Misleading results in the determination of haemolytic disease of the newborn using antibody titration and ADCC in a woman with anti-Lub
36. Maternal antibodies against fetal blood group antigens A or B, lytic activity of IgG subclasses in monocyte-driven cytotoxicity and correlation with ABO haemolytic disease of the newborn
37. The effect of specificity on the functional activity of red cell-bound blood group antibodies
38. Molecular basis for a polymorphism of human FcγRII (CD32)
39. 131 allotype is overexpressed in infants with ABO hemolytic disease of the newborn
40. Protection against immune haemolytic disease of newborn infants by maternal monocyte-reactive IgG alloantibodies (anti-HLA-DR)
41. Monocyte-bound monoclonal antibodies inhibit the FcγRI-mediated phagocytosis of red cells: The efficiency and mechanism of inhibition are determined by the nature of the antigen
42. A short albumin method for the determination of isohemagglutinins, particularly incomplete Rh antibodies
43. Papain-treated red cells in the detection of incomplete antibodies
44. Lack of clinical significance of 'enzyme-only' red cell antibodies
45. A prospective study of routine antenatal enzyme antibody screening demonstrates lack of clinical value in predicting haemolytic disease of the newborn
46. Prenatal and perinatal immunohematology: Recommendations for serologic management of the fetus, newborn infant and obstetric patient
47. Red cell antibodies in pregnancy: There is no 'critical titre'
48. Erythropoietic suppression in fetal anaemia because of Kell alloimmunization
49. ADCC and other cellular bioassays for predicting the clinical significance of red cell alloantibodies
50. Functional interactions of red cells sensitized by IgG1 and IgG3 human monoclonal anti-D with enzyme-modified monocytes and FcR-bearing cell lines
51. Serological and immunological characteristics of maternal anti-Rh(D) antibodies in predicting the severity of haemolytic disease of the newborn
52. Manipulative and inherent errors in anti-D quantitation using the AutoAnalyzer
53. Use of discriminant analysis in relating maternal anti-D levels to the severity of haemolytic disease of the newborn
54. Maternal serum anti-D antibody concentration and assessment of rhesus isoimmunization
55. Maternal anti-D concentrations and outcome in rhesus haemolytic disease of the newborn
56. The role of Rh antibodies in haemolytic disease of the newborn
57. Prediction of the outcome of rhesus haemolytic disease of the newborn: Additional information using an ADCC assay
58. Bioassays to determine the clinical significance of red cell alloantibodies based on Fc receptor-induced destruction of red cells sensitized by IgG
59. Monocyte monolayer assay: An efficient noninvasive technique for predicting the severity of hemolytic disease of the newborn
60. Correlation of monocyte monolayer assay, maternal antibody titres and clinical course in hemolytic disease of the newborn (HDN)
61. Predicting hemolytic disease of the newborn: A comparison of the monocyte monolayer assay and the chemiluminescence test
62. Monocyte monolayer assay as a predictor of severity of hemolytic disease of the fetus and newborn
63. Prediction of the severity of HDN: Quantitative IgG anti-D subclass determinations explain the correlation with functional assay results
64. Predicting the severity of rhesus alloimmunization: Monocyte-mediated chemiluminescence versus maternal anti-D antibody estimation
65. In vitro assays to predict the severity of hemolytic disease of the newborn
66. The ability of the chemiluminescence test to predict clinical outcome and the necessity for amniocenteses in pregnancies at risk of haemolytic disease of the newborn